This question addresses the potential of somatic gene editing—the process of altering genes in specific cells of the body (not inherited by offspring)—as a transformative approach to treating chronic diseases such as diabetes, hemophilia, cystic fibrosis, or certain cancers.

With advancements in technologies like CRISPR-Cas9, scientists are now able to precisely target and edit faulty genes directly within the body, potentially offering long-lasting or even permanent cures, as opposed to conventional pharmaceutical treatments that often manage symptoms over a lifetime.